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The only proven effective acute ischemic stroke treatment to achieve recanalization, reduce stroke severity, and 
improve outcome is intravenous thrombolysis with recombi-
nant tPA (tissue-type plasminogen activator) given within 4½ 
hours from symptom onset.1
Partial-to-complete recanalization of larger occluded ves-
sels is achieved in only 1 out of 3 patients who undergo throm-
bolysis. Many stroke patients, therefore, face severe brain 
damage, disability, and death.2 An improved acute treatment 
is urgently needed. Contrast-enhanced sonothrombolysis 
(CEST), encompassing a thrombolytic drug, ultrasound, and 
microbubbles, may be the next step in acute ischemic stroke 
treatment. Transcranial ultrasound weakens fibrin cross-links; 
promotes motion of blood around the clot; increases uptake, 
penetration, and concentration of tPA within the thrombus; 
and thus augments clot lysis.3–6 Intravenous alteplase therapy 
with transcranial ultrasound is safe and may induce higher 
rates of arterial recanalization, as compared with placebo.7,8 
Adding intravenous contrast (microbubbles) induces further 
acceleration of ultrasound-enhanced thrombolysis, leading to 
a more complete recanalization and to a trend toward better 
short- and long-term outcome.9
Previous sonothrombolysis studies, with or without micro-
bubbles, were performed in patients with visible occlusions 
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on computed tomography angiography (CTA).4,7,10,11 Patients 
with visible occlusions constitute 10% to 28% of unselected 
acute ischemic stroke patients.12,13 There are no data on the 
effect of sonothrombolysis in the absence of a visible occlu-
sion. However, sonothrombolysis might also have recanalizing 
effects in minor arteries, arterioles, or even microcirculation, 
that is, in mild strokes with small invisible thrombi.
In NOR-SASS (Norwegian Sonothrombolysis in Acute 
Stroke Study), we hypothesize that in acute stroke patients, 
eligible for intravenous thrombolysis, the clinical effect of 
additional CEST, given within 4½ hours from symptom 
onset, is superior to that of intravenous thrombolysis alone. 
The aims of this phase III study were to assess the effect and 
safety of contrast-enhanced ultrasound treatment in a cohort 
of unselected acute ischemic stroke patients.
Methods
Study Design and Participants
NOR-SASS was designed as a multicenter, prospective, PROBE trial 
(phase III, randomized, open-label, blinded end point), with the aim 
to demonstrate superiority of contrast-enhanced ultrasound treat-
ment (sonothrombolysis) versus sham ultrasound treatment in con-
secutively admitted patients with acute ischemic stroke within 4½ 
hours after stroke onset. All patients were pretreated with intravenous 
thrombolysis, either alteplase or tenecteplase in a 1:1 random fash-
ion. NOR-SASS was superimposed on The NOR-TEST (Norwegian 
Tenecteplase Stroke Trial), which randomizes patients with acute 
ischemic stroke to either tenecteplase or alteplase.14 The NOR-SASS 
study protocol has been published.12 The study is approved by the 
Regional Ethics Committee and the Norwegian Medicines Agency 
and is registered with EudraCT No 201200032341, and the subjects 
gave informed consent. The trial is conducted according to Good 
Clinical Practice: Consolidated guideline (CPMP/ICH/135/95).
The study was conducted at Center for Neurovascular Diseases, 
Department of Neurology, Haukeland University Hospital, Bergen, 
Norway. Patients ≥18 years of age with acute ischemic stroke symp-
toms admitted within 4½ hours of symptom onset were included in 
the study.
Clinical severity was assessed with the National Institutes of Health 
Stroke Scale (NIHSS), and function was assessed with the modified 
Rankin scale (mRS) and Barthel index. All patients underwent CTA 
on admission. Intracranial arterial occlusion on pretreatment CTA 
was not a prerequisite for inclusion because this study also includes 
sonothrombolysis of distal arteries and central perforating arteries. 
Magnetic resonance imaging (MRI) and magnetic resonance angi-
ography or CT/CTA were performed after 22 to 36 hours to verify 
the infarct, assess intracranial recanalization, and detect hemorrhagic 
transformation. All NIHSS and mRS scores at 90 days were assessed 
by a neurologist or research nurses blinded to the given treatment. All 
CT, CTA, and MRI were interpreted by 2 experienced neuroradiolo-
gists blinded to the given treatment.
Randomization and Blinding
NOR-SASS randomized eligible patients to ultrasound, microbub-
bles (SonoVue) plus alteplase/tenecteplase versus sham ultrasound, 
sham microbubbles (NaCl 0.9%) plus alteplase/tenecteplase in a 
1:1 randomization using sealed envelopes (block randomization). 
Patients, treating physicians, radiologist, and nurses were blinded to 
the patients’ study group assignment. Statistically analyzed outcomes 
were assessed after blinding was broken, on the basis of a statistical 
analysis plan finalised before blinding was broken.
Procedures
The use of either tenecteplase or alteplase was specifically allowed 
in this study. Intravenous thrombolysis was initiated within 4½ hours 
after the onset of ischemic stroke symptoms. Tenecteplase was given 
as a bolus in a dose of 0.4 mg/kg, maximum dose 40 mg. Alteplase 
was given in a dose of 0.9 mg/kg (10% bolus+90% infusion during 
1 hour), maximum dose 90 mg. Sonothrombolysis was performed in 
parallel with intravenous thrombolytic treatment.
Before sonothrombolysis, a brief transcranial color-coded duplex 
sonography was performed by an experienced ultrasonographer work-
ing independently from the treating physician. Sonothrombolysis 
was performed with 2 MHz pulse-wave transcranial Doppler (TCD) 
(Nicolet, SONARA; Natus Neurology Incorporate) monitoring for 60 
minutes, using a hand-held TCD probe for the foraminal window or a 
probe in a fixation head-band secured at a stable angle for the temporal 
window. TCD-emitted output power was set at the maximal achiev-
able level with a mechanical index <1.0. Intravenous microbubbles 
(10 mL SonoVue; BRACCO, Switzerland) were given as an infusion 
of 0.3 mL/min for ≈30 minutes, using an infusion pump. In patients 
with a defined occlusion on CTA, ultrasound was applied to the region 
of the occlusion. In patients without a CTA-defined clot/occlusion, the 
investigator judged the clinical picture and applied ultrasound to the 
region in which she/he thought the lesion/clot was located, through 
either the temporal or foraminal window, as appropriate.
In patients with occlusion of perforating arteries, the sample 
volume was set at the depth of the proximal middle cerebral artery 
(MCA)1 segment, that is, at 50 to 55 mm. In distal MCA2 occlusions, 
the sample volume was set at 30 to 40 mm depth. In anterior cerebral 
artery/posterior cerebral artery symptoms, the sample volume was set 
at 60 to 80 mm. A similar algorithm was applied for the foraminal 
window. For proximal basilar artery, the sample volume was set at 
80 mm and at 100 mm for distal basilar artery. The depth setting was 
chosen for monitoring purposes only because a therapeutic effect is 
related to the ultrasound field as such.
In patients without a defined clot on CTA, insonation of the presumed 
region of interest was performed with continuous slight fanning of the 
ultrasound beam. Sham sonothrombolysis was performed with the 2 
MHz TCD probe plugged into an inactive channel, and sham ultrasound 
was given for 60 minutes after baseline transcranial color-coded duplex 
sonography examination. An intravenous infusion of sham intravenous 
contrast (NaCl 0.9%) 0.3 mL/min for ≈30 minutes was given using an 
infusion pump. The sound of TCD both in sonothrombolysis and in 
sham sonothrombolysis was muted, and the visual display was turned 
away from the patient, treating physicians, and nurses to keep them 
blinded to the patients’ study group assignment.
Outcomes
Primary study end points were neurological improvement at 24 hours 
and functional handicap at 90 days. Main secondary study safety end 
points included hemorrhagic transformation (hemorrhagic infarct/
hematoma), symptomatic intracerebral hemorrhage (sICH), and 
death.
Early (24 hours) clinical outcome and long-term (day 90) functional 
outcome were assessed in a blinded fashion by a trained stroke nurse 
or neurologist. Early clinical outcome at 24 hours was defined by 
NIHSS score as (1) neurological improvement (NIHSS
24
=0 or reduc-
tion of ≥4 NIHSS points compared with baseline NIHSS
0
) and as 







Long-term outcome at 90 days was defined by mRS score using 
(1) single mRS group comparison; (2) fixed dichotomy (excellent 
outcome=mRS score 0–1 versus unfavorable outcome=mRS score 
2–6 and good outcome=mRS score 0–2 versus bad outcome=mRS 
score 3–6); (3) sliding dichotomy/responder analysis (excellent 
outcome=mRS score 0 with baseline NIHSS score ≤7; mRS score 
0–1 with baseline NIHSS score 8–14; and mRS score 0–2 with base-
line NIHSS score ≥15); and (4) ordinal logistic regression analysis.
Patients were monitored in the stroke unit with NIHSS scoring 
at close intervals for 24 to 36 hours. Safety was determined by the 
incidence of hemorrhagic transformation within 22 to 36 hours of 
treatment on MRI (or CT when MRI was not possible) by 2 neuro-
radiologists blinded to all clinical data. ECASS criteria (European 
Cooperative Acute Stroke Study) were used for classification of 
hemorrhagic transformation.15 sICH was defined as local or remote 








Nacu et al  Sonothrombolysis in Acute Ischemic Stroke   337
parenchymal hemorrhage type 2 on the 22 to 36 hours post-treatment 
imaging scan, combined with a neurological deterioration of ≥4 
points on the NIHSS from baseline or from the lowest NIHSS value 
between baseline and 24 hours, or leading to death (SITS-MOST 
criteria [Safe Implementation of Thrombolysis in Stroke-Monitoring 
Study]).16 Details are published.12
Statistical Analysis
A statistical analysis plan was written in co-operation with the Center 
for Clinical Research, Haukeland University Hospital, before closing 
the database and analyzing the data set. Our NORSTROKE database 
showed that patients treated with thrombolysis (n=223) had a 37% 
improvement of mean NIHSS score from 8.7 to 5.5 (3.2; SD=5.9) 
from admission to day 7. Also, based on previous meta-analysis of 
sonothrombolysis clinical studies7,8,11 and clinical studies on throm-
bolysis in mild stroke,17,18 NOR-SASS aimed at detecting a 15% higher 





= 0.52; power 0.8) and intended to include 276 
patients over 3 to 4 years. Because of the lack of funding, NOR-SASS 
had to be stopped prematurely.
Descriptive statistics are reported as mean values with SD, median 
and interquartile range, or proportions as appropriate. The χ2 test was 
used to analyze equality of proportions. Continuous data were analyzed 
by Student t test or Mann–Whitney U test as appropriate. The Fisher 
exact test was used to analyze categorical data with possibly few patients 
in some cells. The change in NIHSS score between baseline and at 24 
hours was tested in a mixed linear regression analyses with repeated 
measures. The effect of treatment on long-term outcome was tested by 
ordinal logistic regression with mRS score as the dependent variable and 
treatment as an independent variable. We tested that our ordinal logistic 
regression model did not violate the proportional odds assumption.
The primary analyses were based on the intention-to-treat princi-
ple. Additional per-protocol analyses were also performed. The level 
of significance was set at 0.05, and 2-sided tests were used for all 
analyses. Stata 14.1 (StataCorp, College Station, TX) was used for 
all analyses.
Results
Between September 2012 and June 2015, a total of 183 
patients (98 men and 85 women) treated with intravenous 
tPA were enrolled in NOR-SASS and randomized to either 
CEST (n=93) or sham CEST (n=90) (Figure). Table 1 shows 
the baseline characteristics of the patients. The mean age for 
all patients was 68.8 years (SD±16.2), median age 71 years 
(interquartile range, 56–82); range 24 to 100 years. The time 
between symptoms onset and CEST treatment was median 
160 minutes and mean 170 (SD ±69) minutes. Vascular risk 
factors, history of cardiovascular disorders, stroke subtype, 
and demographics were similar in both groups (Table 2). The 
intention-to-treat analysis included 43 stroke mimics (23.5%), 
1 patient (0.5%) who underwent embolectomy, 1 patient 
(0.5%) who was included >4½ hours after symptoms onset, 
1 patient (0.5%) who had contraindication to microbubbles 
and received only ultrasound, and 24 patients (13.1%) with 
premorbid mRS score ≥3 points. Seventeen percent of patients 
had posterior circulation events. The number of stroke mimics 
was balanced between the groups. No serious adverse events 
occurred during the CEST or Sham CEST treatment.
Admission NIHSS and 24-hour NIHSS scores were avail-
able for all 183 patients, of which 133 patients (72.7%) were 
improved, 27 patients (14.8%) were deteriorated, and 23 
patients (12.6%) remained stable. All patients were followed 
for 90 days after study entry. Table 3 shows the primary study 
end points and secondary safety end points.
The primary study end point, early neurological improve-
ment at 24 hours with NIHSS score 0 or with NIHSS score 
improvement of ≥4, was found in 51% of the patients in the 
CEST group compared with 46% in the sham CEST group 
(P=0.50) in the intention-to-treat analysis. In the per-protocol 
analysis, this end point was found in 50% of the patients in 
the CEST group compared with 42% of the patients in the 
sham CEST group (P=0.38). The single end point NIHSS 
score 0 was found in 36% versus 23% of the patients (P=0.07) 
in the intention-to-treat analysis and in 38% versus 22% of 
the patients (P=0.06) in the per-protocol analysis. The single 
end point NIHSS score improvement of ≥4 was found in 29% 
versus 31% of the patients (P=0.76) in the intention-to-treat 
analysis and in 31% versus 27% of the patients (P=0.66) in 
the per-protocol analysis. The data suggest no differences 
between CEST and sham CEST treatment groups in func-
tional outcome at 90 days (excellent mRS 0–1: 50% versus 
53%; P=0.77; Table 3).
On admission, CT and CTA scans were performed in all 
patients. After 22 to 36 hours, control MRI was performed 
in 89% and control CT in 10%. sICH occurred in 2 patients 
in the CEST group and 4 in the sham CEST group (2% ver-
sus 4%; P=0.38). Asymptomatic intracranial hemorrhage on 
control MRI/CT occurred in 11 patients in each treatment 
groups (14.0% versus 17%; P=0.93). NOR-SASS did not 
have any cases of sICH among stroke mimics, neither in the 
CEST nor in the sham CEST groups. There were 6% deaths in 
CEST group compared with 9% deaths in sham CEST group 
(P=0.53) in the intention-to-treat analysis and 3% deaths in 
CEST group compared with 7% deaths in sham CEST group 
(P=0.60) in the per-protocol analysis. Early death caused 
by sICH occurred in 2 patients (1%), one in each treatment 
group. No statistically significant differences were noted for 
any primary and secondary safety study end points. Table 4 
shows ordinal logistic regression with mRS as outcome vari-
able and CEST treatment as the explanatory variable.
Twenty-six stroke patients (19%) had an arterial occlu-
sion on CTA. Sixteen patients (11.5%) had total MCA1 or 
MCA2 occlusion on admission. After 24 hours, 8 patients had 
no signs of recanalization (37.5% CEST versus 62.5% sham 
CEST), and 8 patients had partial to full recanalization (62.5% 
CEST versus 37.5% sham CEST; P=0.18).
NOR-SASS included 7 patients with confirmed acute isch-
emic stroke diagnosis who were randomized to CEST and 
received inappropriate insonation because of incorrect local-
ization of the potential intracranial occlusion. Six patients 
had a posterior circulation stroke and were insonated via the 
transtemporal window; 1 patient had MCA stroke and was 
insonated via the foramen magnum window. These patients 
were not excluded from the per-protocol analysis because 
the protocol did not foresee this possibility as an exclusion 
criteria.
Discussion
NOR-SASS shows that in an unselected acute ischemic stroke 
population CEST given within 4½ hours after stroke onset is 
safe. Neither bleeding nor death was increased. The safety 
of CEST was not modified by stroke severity. Our findings, 
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therefore, suggest that CEST using 2 MHz pulse-wave TCD 
monitoring for 60 minutes is safe in patients with varying 
grades of clinical severity, with or without a visible occlusion 
on CTA and thus with large or small thrombi.
There have been concerns about safety of CEST in acute 
ischemic stroke patients.10,19,20 NOR-SASS does not sup-
port this concern. In NOR-SASS, sICH occurred in 3% 
and asymptomatic intracerebral hemorrhage in 12% of all 
patients included. This is comparable to previous CEST 
studies in patients with MCA occlusion, reporting sICH in 
0% to 27% and asymptomatic intracerebral hemorrhage in 
23% to 75% of patients.9,10,19 Early death caused by sICH 
was 1% in NOR-SASS, compared with ≈3% in patients 
treated only with tPA.21 A higher number of microbleed-
ings are detected with MRI compared with CT.20 Use of 
MRI as a 22- to 36-hour imaging modality in the NOR-
SASS study may, therefore, account for the overall high 
rate of cerebral bleeding complications even among mild 
stroke patients.
NOR-SASS is a neutral study as to clinical effect. There 
was an overall trend toward a higher percentage of patients 
reaching the primary end points in the CEST group, but the 
differences did not reach statistical significance.
NOR-SASS aimed to include 276 patients. Because of lack 
of funding, NOR-SASS study had to be stopped prematurely 
after including only 183 patients. This low number may have 
contributed to the overall neutral results of the study.
NOR-SASS is the first randomized study of CEST in an 
unselected acute ischemic stroke population, mostly without 
a visible clot on the baseline CT. Patients treated may, there-
fore, have had small clots in arterial branches or disseminated 
occlusions in the microcirculation or both. Clinical data on 
the effect of CEST treatment on the cerebral microcircula-
tion are lacking. In vivo and in vitro studies have, however, 
demonstrated beneficial effects of CEST on occlusion of 
small vessels down to the capillary level and reperfusion of 
the microvasculature.22–24 An in vitro flow model of partially 
occluded microcirculation demonstrated more rapid and com-
plete clot lysis after CEST.22 A recent in vitro study exam-
ined microscale evolution of the erosion front of blood clots 
exposed to ultrasound stimulated microbubbles.25 The devel-
opment of a complex zonal erosion pattern was observed. The 
fibrin zone architecture was dependent on exposure condi-
tions forming large-scale tunnels.25 An in vivo study with a 
reperfusion model in rats showed beneficial effects of CEST 
on the level of the microvasculature, resulting in complete 
Figure. Trial profile. CEST indicates con-
trast-enhanced sonothrombolysis; mRS, 
modified Rankin scale; NIHSS, National 
Institutes of Health Stroke Scale; and 
NOR-SASS, Norwegian Sonothromboly-
sis in Acute Stroke Study.
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reversal of flow obstruction, decreased ischemic lesion vol-
ume, and decreased edema formation.23,24 Comparing pub-
lished clinical trials of CEST treatment with NOR-SASS is 
difficult because of the wide range of treatment protocols, dif-
ferent end points, and limited number of patients. The NOR-
SASS population differs substantially from those in previous 
CEST trials. Previous trials were conducted in selected stroke 
populations with visible thrombi in major intracranial arteries 
on CT/CTA, mostly MCA occlusions.9,19,26,27 To our knowl-
edge, NOR-SASS is the first clinical trial that studied the 
effect and safety of CEST in an unselected stroke popula-
tion, predominantly with mild stroke without visible thrombi 
on admission CTA. This group includes 70% to 80% of all 
acute ischemic stroke patients.12,13 Mild stroke with small 
thrombi have a higher recanalization rate after intravenous 
thrombolysis.28 It is, therefore, conceivable that also ultra-
sound may have a better effect on small arterial thrombi and 
on microcirculation.23 NOR-SASS indicates that CEST may 
be a therapeutic strategy for patients with persistent hypo-
perfusion (no reflow phenomenon) of the microvasculature, 
for which there is currently no direct therapy. We could, 
however, not show a significant clinical effect of CEST in 
these patients. The NIHSS score of median 4 to 5 point on 
admission suggests mild strokes, in which it may be difficult 
to achieve a positive result because of a ceiling effect. There 
was a contradictory trend between improvements in NIHSS 
score at 24 hours in favor of CEST, which was not seen in 
mRS at 3 months. Reasons for this may be that mRS outcome 
measures are insensitive to minor neurological improvement 
at 3 months or even an insufficient effect of CEST. A larger 
number of patients and more sensitive outcome measures 
should be applied in future studies with adequate power. 
NOR-SASS was superimposed in NOR-TEST trial. Using 
2 different thrombolytic agents (tenecteplase and alteplase) 
in well-balanced NOR-SASS randomization (1:1) has not 
affected the study results as such. After NOR-TEST trial is 
finished, the NOR-SASS results on CEST with tenecteplase 
versus alteplase will be published.
In previous sonothrombolysis study patients with NIHSS 
≥10 points has been shown to have a high positive predictive 
value (>95%) for proximal intracranial occlusion both in the 
anterior and posterior circulation.29 Moreover, in a subgroup 
analysis of CLOTBUST (Combined Lysis of Thrombus in 
Brain Ischemia With Transcranial Ultrasound and Systemic 
Table 1. Characteristics of the Patients at Baseline
Variables CEST (n=93) Sham CEST (n=90) P Value
Mean age±SD, y* 70±16 68±16 0.24
Male sex, n (%) 54 (55) 44 (45) 0.21
NIHSS score
  Median (IQR) 4 (2–8) 5 (3–10) 0.44
mRS score
  Median (IQR) 0 (0–2) 0 (0–2) 0.50
   0–n (%) 65 (70) 58 (64) 0.44
   1–n (%) 5 (5) 7 (8) …
   2–n (%) 7 (8) 11 (12) …
   ≥3–n (%) 16 (17) 14 (16) …















Mean systolic blood 
pressure±SD, mm Hg
160±26 155±25 0.21
Mean diastolic blood 
pressure±SD, mm Hg
85±16 86±14 0.63
CEST indicates contrast-enhanced sonothrombolysis; CRP, C-reactive 
protein; IQR, interquartile range; mRS, modified Rankin scale; and NIHSS, 
National Institutes of Health Stroke Scale.
*Plus-minus values are given as means±SD.
Table 2. Vascular Risk Factors, History of Cardiovascular 
Disease, and Stroke Subtypes
Variable CEST (n=93) Sham CEST (n=90) P Value
Vascular risk factors, n (%)
  Hypertension 45 (48) 43 (48) 0.93
  Diabetes mellitus 11 (12) 14 (16) 0.44
  Paroxysmal atrial 
fibrillation
14 (15) 10 (11) 0.43
  Chronic atrial fibrillation 7 (8) 6 (7) 0.82
  Smoking 18 (20) 20 (25) 0.46
History of cardiovascular disease, n (%)
  Ischemic stroke 20 (22) 15 (17) 0.44
  Transient ischemic attack 11 (12) 6 (7) 0.23
  Myocardial infarction 12 (14) 12 (14) 0.97
  Angina pectoris 12 (13) 10 (11) 0.73
  Peripheral arterial disease 7 (8) 3 (3) 0.20
  Any cardiovascular disease 46 (51) 36 (42) 0.24
Stroke subtype, n (%) 0.54
  Large-artery 
atherosclerosis
8 (11) 4 (6)  
  Cardioembolism 19 (26) 26 (39)  
  Small-vessel occlusion  7 (10) 4 (6)  
  Stroke of other determined 
cause
1 (1) 0 (0.0)  
  Stroke of undetermined 
cause
39 (53) 32 (49)  
Stroke in the posterior 
circulation
10 (11) 14 (16) 0.33
CEST indicates contrast-enhanced sonothrombolysis.
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tPA), sonothrombolysis seemed to have greater efficacy in 
terms of 3-month functional outcome in this specific stroke 
subgroup.30 In NOR-SASS, the patients with NIHSS ≥10 
points were thus too few to be analyzed and came with some 
conclusions.
Strengths of NOR-SASS, albeit with a low number of 
patients, are it being the first pragmatic randomized controlled 
trial on CEST in an unselected stroke population, being 
the biggest CEST study till now, and having well-balanced 
treatment groups and complete follow-up data at 90 days. 
Nevertheless, NOR-SASS showed new results in a specific 
population of acute stroke patients, who have not yet been 
investigated. The high rate of MRI controls renders data on 
infarcts and bleedings (symptomatic and asymptomatic) reli-
able. NOR-SASS, therefore, was performed in a clinically 
highly relevant setting.
As expected, the pragmatic decision to include mild 
strokes and use CT as baseline imaging modality increased 
the number of stroke mimics and reduced the chance of 
detecting a significant difference between the treatment 
groups. Using MRI at admission may decrease the number 
of stroke mimics but will increase the time to treatment. 
Also, not every hospital has access to acute MRI. The proto-
col is, therefore, suitable also for smaller hospitals. A weak-
ness of NOR-SASS is the accidental inclusion of a high 
number of presumably functional independent patients, who 
after investigations turned out to have pretreatment mRS ≥3 
points and thus had to be excluded from the per-protocol 
analysis.
In conclusion, we found that CEST is safe when given 
within 4½ hours after stroke onset to acute ischemic stroke 
patients with varying grades of clinical severity, with or 
without a visible occlusion on CTA and thus with larger 
or smaller thrombi. An overall clinical effect could not be 
shown in the small number of patients included. NOR-SASS 
demonstrates, however, the potential of CEST treatment 
as a pragmatic adjuvant therapy for acute ischemic stroke 
patients.
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Table 3. Primary and Secondary Clinical and Safety Study End Points
Intention-to-Treat Analysis Per-Protocol Analysis
CEST (n=93) Sham CEST (n=90) P Value CEST (n=58) Sham CEST (n=55) P Value
Primary study end points, n (%)
  Neurological improvement at 24 h with NIHSS 0 
or NIHSS ≥4 points
47 (51) 41 (46) 0.50 29 (50) 23 (42) 0.38
  Neurological improvement at 24 h with NIHSS 
score 0
33 (36) 21 (23) 0.07 22 (38) 12 (22) 0.06
  Neurological improvement at 24 h with ≥4 NIHSS 
points
27 (29) 28 (31) 0.75 18 (31) 15 (27) 0.66
  Score of 0–1 on modified Rankin scale at 90 d 45 (48) 46 (51) 0.71 29 (50) 28 (53) 0.77
  Score of 0–2 on modified Rankin scale at 90 d 57 (61) 63 (70) 0.21 39 (67) 42 (76) 0.28
  Excellent outcome (sliding dichotomy)* 26 (28) 31 (34) 0.34 9 (16) 11 (20) 0.53
Secondary safety study end points n (%)
  Asymptomatic intracerebral hemorrhage 11 (14) 11 (17) 0.38 10 (17) 10 (18) 0.89
  Symptomatic intracerebral hemorrhage† 2 (2) 4 (4) 0.13 2 (3) 3 (6) 0.60
  Death 6 (6) 8 (9) 0.22 2 (3) 4 (7) 0.42
The P values were derived from the χ2 test, Student t test, and Wilcoxon rank-sum test, as appropriate. CEST indicates contrast-enhanced 
sonothrombolysis; mRS, modified Rankin Scale; and NIHSS, National Institutes of Health Stroke Scale.
*Sliding dichotomy defined excellent outcome as mRS score 0 with baseline NIHSS score ≤7; mRS score 0–1 with baseline NIHSS score 8–14; 
and mRS score 0–2 with baseline NIHSS score ≥15.
†Symptomatic intracerebral hemorrhage was defined as local or remote parenchymal hemorrhage type 2 on the 22–36 h post-treatment imaging scan, 
combined with a neurological deterioration of ≥4 points on the NIHSS from baseline or from the lowest NIHSS value between baseline and 24 h, or leading 
to death.
Table 4. Ordinal Logistic Regression With mRS as Outcome 
Variable and CEST Treatment as the Explanatory Variable
 OR 95% CI P Value
CEST (ITTA) 1.21 0.722–2.01 0.47
CEST (PPA) 1.31 0.68–2.54 0.41
CEST indicates contrast-enhanced sonothrombolysis; CI, confidence interval; 
ITTA, intention-to-treat analysis; mRS, modified Rankin Scale; OR, odds ratio; 
and PPA, per-protocol analysis.
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